证券研究报告 绿联科技 (301606 CH) 营收增长提速，看好全年净利弹性 华泰研究 季报点评 2025 年 4 月 29 日│中国内地 零售 公司发布一季报：1Q25 实现营收 18.24 亿元，同比+42.0%，归母净利润 1.50 亿元，同比+47.2%。我们认为，1Q25 收入高增长主要得益于全球化 战略的不断落地，叠加新品上市后销售效果良好。展望后续，我们预计在产 品矩阵不断扩充的加持下，公司加速渗透非美市场（欧洲、东南亚等）的逻 辑有望持续兑现，同时 NAS 存储或将进入放量增长的新阶段，公司经营持 续向好，利润弹性可期，维持"买入"评级。 推新不断完善产品矩阵，营收增长提速 1Q25 营收同比+42.0%，增速较 4Q24 提升 13.5pct，我们认为主要系新品 驱动。2024 年公司通过加大研发投入，不断推出新产品和更新迭代现有品 类，在国内外市场进行产品矩阵的补充优化和推广，比如高瓦数氮化镓快充 产品、第二代 NAS 云存储产品和 TWS 耳机。上述新品的导入助推 1Q25 营收加速增长。在 2025 年 1 月举办的 CES 展上，绿联科技展出 AI NAS、 Nexode 500W ...

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of RMB 17.66 [8][10]. Core Views - The company demonstrates strong profitability with a year-on-year increase in net profit and operating income of 17.3% and 2.2% respectively for Q1 2025, maintaining a high annualized ROE of 20.60% [1]. - Credit growth remains robust, with total assets, loans, and deposits increasing by 15.9%, 14.3%, and 21.1% respectively as of March 2025 [2]. - Non-interest income continues to grow, with a 22.2% increase in fee-based income, contributing to 14.1% of total revenue [3]. - Asset quality remains stable, with a non-performing loan ratio of 0.76% and a provision coverage ratio of 530% as of March 2025 [4]. - The company is projected to achieve a net profit of RMB 19.55 billion in 2025, reflecting a growth rate of 15.1% [5]. Summary by Sections Profitability and Growth - The company reported a net profit of RMB 19.55 billion for 2025, with a projected growth of 15.1% [5]. - The annualized ROE and ROA for Q1 2025 are 20.60% and 1.11% respectively, indicating strong profitability [1]. Credit and Asset Quality - As of March 2025, total assets, loans, and deposits grew by 15.9%, 14.3%, and 21.1% respectively compared to the end of 2024 [2]. - The non-performing loan ratio stands at 0.76%, with a provision coverage ratio of 530%, indicating solid asset quality [4]. Non-Interest Income and Cost Management - Non-interest income decreased by 5.4% year-on-year, while fee-based income increased by 22.2%, contributing to a higher proportion of total revenue [3]. - The cost-to-income ratio improved to 23.7%, reflecting operational efficiency [3]. Capital and Valuation - The capital adequacy ratio and core tier 1 capital ratio are 14.05% and 9.01% respectively, showing a healthy capital position [4]. - The target price of RMB 17.66 corresponds to a price-to-book ratio of 0.91 for 2025, indicating a premium valuation compared to peers [5].

Investment Rating - The investment rating for the company is "Buy" [9][10] Core Views - The company's Q1 revenue was 735.4 billion RMB, showing a decrease of 7% quarter-on-quarter but an increase of 4% year-on-year. The net profit attributable to shareholders was 13.3 billion RMB, which is a decrease of 28% quarter-on-quarter but an increase of 119% year-on-year [1] - The report highlights that the traditional business faces profit pressure, while non-oil business shows promising performance. The chemical sector has reduced losses, and the marketing segment's non-oil business has exceeded expectations [1][4][5] - The report maintains a positive outlook for the company's profitability recovery in the refining industry post-2025, supported by its integrated advantages and transformation into new materials [6] Summary by Sections Financial Performance - Q1 oil production was 69.5 million barrels, down 1.2% year-on-year, with an average oil price of 71.5 USD/barrel, down 5.2%. Natural gas production increased by 5.1% to 368.4 billion cubic feet [2] - The refining segment's Q1 operating profit dropped significantly by 44.3 billion RMB to 19.8 billion RMB due to high oil inventory costs, with refining margins narrowing to 6.2 USD/barrel, down 13.9% year-on-year [3] - The marketing segment's total domestic refined oil sales decreased by 5.3% year-on-year, leading to a profit drop of 39.8 billion RMB to 39.7 billion RMB [4] Chemical Sector - The chemical segment's production of ethylene, synthetic resin, and fiber monomers increased by 18%, 17%, and 27% year-on-year, respectively. The segment's losses were reduced by 4.7 billion RMB year-on-year [5] Profit Forecast and Valuation - The company maintains profit forecasts for 2025-2027 at 53.9 billion RMB, 58.8 billion RMB, and 61.6 billion RMB, respectively, with EPS projected at 0.44, 0.48, and 0.51 RMB [6] - The target prices are set at 6.82 RMB for A-shares and 4.73 HKD for H-shares, reflecting a valuation of 15.5x PE for 2025 [6]

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [2][20]. Core Insights - The company's main business is experiencing a strong recovery, and its humanoid robot business is poised for significant growth. The automotive parts segment has solidified its advantages, with a notable increase in profitability. The company has strategically positioned itself in the humanoid robot core components market, achieving domestic substitution and reducing production costs [2][7][8]. Financial Performance Summary - For 2024, the company is projected to achieve total revenue of 49.10 billion yuan, representing a year-on-year growth of 18.64%. The net profit attributable to the parent company is expected to reach 4.97 billion yuan, a substantial increase of 514.49% [7][8]. - Revenue forecasts for 2025, 2026, and 2027 are 55.78 billion yuan, 65.52 billion yuan, and 78.73 billion yuan, with respective growth rates of 13.6%, 17.5%, and 20.2% [3][8]. - The net profit attributable to the parent company is projected to be 5.34 billion yuan in 2025, 6.17 billion yuan in 2026, and 7.67 billion yuan in 2027, with growth rates of 7.4%, 15.7%, and 24.3% respectively [3][8]. Business Segment Analysis - The automotive parts business has strengthened its position, with key products like seat horizontal actuators being supplied to major automakers such as BYD and Changan. The company has also made significant advancements in electric drive systems for popular models [7][8]. - The humanoid robot screw business is expected to open a second growth curve, with the company achieving domestic production of key components and establishing a trial production line for 12,000 sets by the end of 2024 [7][8]. Market Position and Strategy - The company is capitalizing on domestic substitution opportunities and accelerating its global layout, with new subsidiaries established in Thailand and Singapore to enhance supply chain responsiveness and cost advantages [7][8]. - The report highlights the company's strategic moves, including the divestiture of loss-making businesses and the optimization of its cost structure, which has led to improved operating cash flow [7][8].

Investment Rating - The investment rating for Ningbo Bank is "Buy" and it is maintained [5]. Core Views - Ningbo Bank reported a revenue of 18.5 billion yuan in Q1 2025, representing a year-on-year growth of 5.63%, and a net profit attributable to shareholders of 7.4 billion yuan, also up by 5.76% year-on-year [1][2]. - The bank's asset quality continues to improve, with a non-performing loan (NPL) ratio of 0.76% and a provision coverage ratio of 370.54% as of the end of Q1 2025, indicating stable risk compensation capabilities [3]. - The bank is expected to maintain high growth in both deposits and loans, with projections for revenue and profit growth of 8.36% and 8.19% respectively for 2025 [4]. Performance Summary - Revenue and net profit growth rates for Q1 2025 were 5.63% and 5.76%, respectively, which are slightly lower than the previous year's growth rates [2]. - Net interest income increased by 11.59% year-on-year, although the net interest margin decreased to 1.80%, down by 6 basis points from the previous year [2]. - Fee and commission income decreased by 1.32% year-on-year, while other non-interest income fell by 7.18% [2]. Asset Quality - The NPL generation rate for Q1 2025 was 1.09%, showing a decline of 8 basis points from the previous quarter, continuing a downward trend since Q1 2024 [3]. - The bank's write-off amount for Q1 2025 was 3.05 billion yuan, with recoveries amounting to 670 million yuan [3]. Asset and Liability Management - As of Q1 2025, total assets and loans reached 3.40 trillion yuan and 1.64 trillion yuan, respectively, with year-on-year growth rates of 17.58% and 20.41% [4]. - Total deposits amounted to 2.18 trillion yuan, reflecting a year-on-year increase of 19.92% [4].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company achieved a total revenue of 16.82 billion yuan in 2024, representing a year-on-year increase of 14.8%, and a net profit attributable to shareholders of 1.05 billion yuan, up 7.8% year-on-year [1] - The company experienced strong growth in overseas sales, with a 21.7% increase in foreign revenue for 2024, while domestic sales faced pressure with a decline of 4.4% [2] - The gross margin for 2024 decreased by 1.8 percentage points to 20.9%, primarily due to intensified market competition and changes in sales structure [3] - In Q1 2025, the company reported a revenue of 3.83 billion yuan, a year-on-year increase of 10.4%, and a net profit of 250 million yuan, up 43.0% year-on-year [1][4] Revenue Breakdown - For 2024, the company's revenue from kitchen appliances was 11.51 billion yuan, up 16.3%, while home appliances revenue was 2.92 billion yuan, up 17.4% [2] - The revenue from global ODM/OEM and proprietary brands in 2024 was 14.34 billion yuan and 2.48 billion yuan, respectively, with year-on-year changes of +20.1% and -8.3% [2] Profitability Metrics - The net profit margin for 2024 was 6.6%, down 0.5 percentage points year-on-year [3] - In Q1 2025, the gross margin improved to 22.4%, an increase of 0.5 percentage points year-on-year, attributed to cost reduction and efficiency enhancement measures [4] Future Profit Forecast - The company is expected to achieve net profits of 1.16 billion yuan, 1.27 billion yuan, and 1.38 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 10.5%, 9.4%, and 8.5% [4]

证券研究报告·公司点评报告·医疗器械 鱼跃医疗（002223） -16% -13% -10% -7% -4% -1% 2% 5% 8% 11% 14% 17% 2024/4/29 2024/8/28 2024/12/27 2025/4/27 鱼跃医疗 沪深300 2024 年报及 2025 年一季报点评：25Q1 季报 高基数下好于预期，期待新品快速增长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 7,972 | 7,566 | 8,760 | 10,134 | 11,711 | | 同比（%） | 12.25 | (5.09) | 15.78 | 15.69 | 15.56 | | 归母净利润（百万元） | 2,396 | 1,806 | 1,954 | 2,211 | 2,540 | | 同比（%） | 50.21 | (24.63) | 8.19 | 13.15 | 14.91 | | EPS-最新摊薄 ...

Investment Rating - The report maintains a "Recommended" rating for Baowu Magnesium Industry [5][11]. Core Views - The company achieved a revenue of 8.983 billion yuan in 2024, a year-on-year increase of 17.39%, but the net profit attributable to shareholders decreased by 47.91% to 160 million yuan due to low magnesium prices and increased operating expenses [2][10]. - The production and sales of magnesium-aluminum alloy products continue to grow, with production increasing by 27.81% to 460,000 tons and sales up by 23.54% to 450,000 tons in 2024 [3]. - The company is increasing its research and development investment, which rose from 309 million yuan in 2021 to 455 million yuan in 2024, accounting for 5.1% of revenue [4]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 8.983 billion yuan, with a net profit of 160 million yuan, and basic earnings per share of 0.16 yuan, reflecting a decrease of 50.93% year-on-year [2]. - For Q1 2025, the company achieved a revenue of 2.033 billion yuan, a 9.08% increase year-on-year, but the net profit decreased by 53.58% to 28 million yuan [2]. Production and Sales - The production of magnesium-aluminum alloy and deep-processed products saw a dual increase in 2024, with production up by 27.81% and sales up by 23.54% [3]. - The company has a current magnesium alloy capacity of 200,000 tons and aluminum alloy capacity of 150,000 tons, with plans to increase magnesium alloy capacity by 150% to 500,000 tons [3]. R&D and Market Development - The company is focusing on R&D to enhance the application of magnesium alloys in various sectors, including automotive lightweighting and robotics [4]. - A significant breakthrough was achieved in collaboration with Seres, leading to the development of the world's largest integrated die-casting magnesium alloy rear body for mass production [4]. Future Projections - The company is projected to achieve revenues of 10.916 billion yuan, 14.398 billion yuan, and 15.864 billion yuan for 2025, 2026, and 2027 respectively, with net profits expected to reach 452 million yuan, 785 million yuan, and 905 million yuan [11][12].

Investment Rating - The report maintains a "Recommended" rating for the company [2][7]. Core Views - The company experienced a revenue decline of 1.71% year-on-year in 2024, with total revenue reaching 1.868 billion yuan. The net profit attributable to shareholders decreased by 37.67% to 84 million yuan [3]. - The company is facing short-term pressure, but new channels are seen as a bright spot for growth [4][7]. - The company has expanded its customer base, increasing the number of major clients to 173, which is an 8.81% year-on-year increase [4]. Revenue and Profitability - In 2024, the company's revenue from direct sales was 809 million yuan, up 4.34% year-on-year, while revenue from distribution channels fell by 6.04% to 1.051 billion yuan [4]. - The company’s gross margin for 2024 was 23.66%, a slight decrease of 0.04 percentage points year-on-year [6]. - The company’s sales expense ratio increased by 0.72 percentage points to 5.40% due to intensified competition and increased marketing efforts [6]. Product Performance - Revenue from fried products decreased by 11.87% to 767 million yuan, while revenue from steamed products grew by 5.41% to 393 million yuan, driven by strong demand for prepared foods [5]. - The company’s revenue from prepared dishes and other products increased by 21.84% to 360 million yuan, indicating a growing market for prepared foods [5]. Future Earnings Forecast - The company’s net profit is projected to be 93 million yuan in 2025, 104 million yuan in 2026, and 113 million yuan in 2027, with corresponding earnings per share (EPS) of 0.95, 1.07, and 1.16 yuan respectively [7][13].

证券研究报告 宏川智慧 (002930 CH) 石化仓储需求偏弱，拖累盈利 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 29 日│中国内地 | 仓储物流 | 宏川智慧发布 2024 年及 1Q25 业绩：1）24 年公司营收 14.5 亿元，同比 -6.3%；归母净利 1.6 亿元，同比-46.6%，低于我们的预期（2.6 亿元）。2） 1Q25 公司营收 3.2 亿元，同比-15.0%；归母净利 2,095 万元，同比-65.1%。 24 年及 1Q25 盈利同比大幅下降主因下游石化行业需求偏弱，导致公司储 罐及化工仓库出租率和价格下降，但折旧成本相对刚性，拖累盈利。展望 25 年，受关税影响，全球宏观经济存较大不确定性。我们预计整体石化仓 储需求或仍偏弱，但考虑公司新增项目投产，我们预计公司 25 年盈利在 24 年低基数上同比有望小幅改善。维持"增持"。 24 年石化行业需求偏弱，仓储物流行业盈利承压 2024 年公司新增项目并购使业务规模提升，但受下游石化需求偏弱影响， 经营业绩承压。24 年公司毛利润 7.2 亿元，同 ...